Drugs targeting the G protein-coupled receptor (GPCR) superfamily comprise the vast majority of approved small molecule therapeutics on the market today. As a deeper understanding of the functions of GPCRs has been accumulated, novel approaches are being explored in the discovery of the next generation of GPCR drugs.

Our integrated program teams have discovered and delivered several novel GPCR development candidates to our partners across multiple therapeutic areas, including inflammation, respiratory and CNS. Regardless of the stage your GPCR project is in, partner with us to ensure you are making the right decision on your preclinical journey.